Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNK013
- Development stage
- Preclinical
- Lead developer
- Lynk Pharmaceuticals
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
LNK013 is an oral, small-molecule proteolysis-targeting chimera (PROTAC) designed to selectively degrade interleukin-1 receptor-associated kinase 4 (IRAK4). Developed by Lynk Pharmaceuticals, LNK013 is being investigated for the treatment of inflammatory and autoimmune diseases, specifically atopic dermatitis and hidradenitis suppurativa. By targeting IRAK4 for proteasomal degradation, LNK013 aims to block downstream signaling pathways mediated by toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs), which are key drivers of chronic inflammation. The drug is currently in preclinical development.
02
Targets
CRBN (Cereblon)IRAK4 (Interleukin-1 receptor associated kinase 4)
Beyond the preview
Go deeper on LNK013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNK013.